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The State and Employment in Liberal Market Economies: Industrial Policy in the UK 
Pharmaceutical and Food Manufacturing Sectors 
 
Introduction 
Over the last two decades social scientists from various fields have shown great interest in 
issues of comparative political economy, in particular in examining the adjustment of 
national economies to processes of globalisation and intensifying international competition 
(Whitley 1999; Hall and Soskice 2001; Amable 2003). A key contribution of this research 
has been how it has demonstrated that economic activity continues to be largely influenced 
and shaped by the particular institutions, regulatory frameworks and cultures within 
individual and groups of countries.  
 
The most high profile recent example in this vein is the literature adopting a varieties of 
capitalism framework. A central feature of this approach is the distinction it draws between 
two basic but contrasting types of economy, namely liberal market economies and 
coordinated market economies. It is argued that economic activity in liberal market 
economies such as the US and UK, is predominantly characterised by market transactions 
undertaken by atomistic firms. In contrast, varieties of capitalism authors highlight how in 
coordinated market economies such as Germany and Japan individual firms tend to be 
embedded into local, regional or sectoral networks, with non-market forms of economic 
regulation more prevalent (Hall and Soskice 2001).  
 
The varieties of capitalism approach has both deepened understanding and generated critical 
debates and perspectives regarding the analysis of models of capitalism. Important perceived 
weaknesses of prevailing frameworks include the insufficient attention given to the role of 
the state in shaping economic and regulatory trajectories, and a failure to recognise the extent 
of heterogeneity existing within national economies (Crouch 2005; Howell 2007; Weiss 
2010; Lane and Wood 2011). 
 
The varieties of capitalism literature has been extensively referenced by employment 
scholars, with research from a varieties of capitalism perspective examining the impact of 
different institutional frameworks and governance regimes on employment outcomes, wage 
levels and skills (Estévez-Abe, Iversen and Soskice 2001; Doellgast, Holtgrewe and Deery 
2009; Batt, Nohara and Kwon 2010).  
 
The focus of this chapter is on addressing one of the key gaps in the varieties of capitalism 
literature, namely the inadequate attention given to the role of the state. We explore the 
impact of the state on employment in liberal market economies, with a particular focus on 
state industrial policy. Specifically, we examine the employment implications of state 
industrial policy in the UK pharmaceutical and food manufacturing sectors. In this way the 
chapter responds to calls for the connection of labour process research to ‘a broader political 
economy’ (Thompson 2003; Thompson and Vincent 2010). 
 
We draw on secondary sources, including previous academic research; official statistics; 
government, state agency and industry body reports; periodicals and other news sources. This 
is supplemented with primary data consisting of interviews with policy makers, industry 
officials, senior managers and operational employees within the UK dairy processing and 
pharmaceutical sectors, undertaken in 2003-4 and 2008-2010 respectively.  
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Our research identified substantial differences in state industrial policy towards the two 
sectors, which in turn underpinned divergent outcomes relating to employment, working 
conditions and skills. In pharmaceuticals a strategic and resource-intensive industrial policy 
on the part of government has enabled the UK sector to perform strongly and led to the 
creation of high quality jobs. In contrast, in food manufacturing the predominant reliance on 
market mechanisms has negatively impacted industry performance and resulted in poor job 
quality and deteriorating working conditions.  
 
These findings illustrate the problematic nature of dominant paradigms and policy 
prescriptions regarding the role of the state in liberal market economies within the literature 
on comparative capitalism. In contrast, the positive potential impact of active state industrial 
policies on employment is emphasised. The chapter highlights the various ways in which 
governments in liberal market economies intervene in the economy and the important 
employment consequences of this, again challenging prevailing analytical frameworks.  
 
The chapter first considers existing theory and research on the role of the state in liberal 
market economies. Next the definition and nature of state industrial policy is considered. The 
main findings regarding UK government industrial policy and its impact on employment in 
the pharmaceutical and food processing sectors are then presented. Finally, an analysis and 
conclusion is provided.   
 
The Role of the State in Liberal Market Economies 
Dominant Conceptions 
In the varieties of capitalism framework, the primary function of the state in liberal market 
economies is seen to be to ensure the free operation of market forces, as this it is argued is the 
most effective method of coordinating firms and economic activity and hence enhancing 
economic welfare in such countries (Hall and Soskice 2001).  
 
In his elaboration of national business systems, Whitley (1999, 2005) presents the ‘arm’s-
length state’ as a distinctive type of state approach to economic management and regulation, 
and notes how most so-called liberal market economies tend to be characterised by such an 
approach. He notes how arm’s length states tend to concentrate on establishing and enforcing 
the framework and rules within which market transactions take place, while leaving the 
nature of economic activity and organisation within these frameworks to be largely freely 
determined by relevant economic and social actors.  
 
Schmidt (2002) identifies ‘market capitalism’ as one of three main types of capitalism in 
Europe, while Amable’s (2003) more wide-ranging study identifies ‘market-based’ systems 
as a distinct model. For these and the above authors, countries such as the US and UK that 
are conventionally described as liberal market economies, are distinctive because of their 
emphasis on competitive markets as the central drivers of growth and the predominantly 
hands-off role of the state in economic management.   
    
Theoretical and Empirical Critique 
Although typically presented as ideal types, these dominant conceptions of the role of the 
state in so-called liberal market economies are properly subject to both theoretical and 
empirical critique. In this regard, authors adopting a ‘regulation approach’ highlight the 
pervasive influence of the state on the economic sphere (Boyer 1990; Jessop 2002). For 
Boyer (1990: 42), the state ‘plays a definite role in the establishment, rise, and crisis of every 
regime of accumulation.’  
3	  	  
 
Following Polanyi, Block (1994) notes how even in market-dominated systems, the state 
strongly shapes economic activity. Rueschemeyer and Evans (1985: 45) observe how in 
idealized market models, ‘collective goods’ will be inadequately provided and ‘negative 
externalities’ not controlled, which calls for state action to address these problems. Moreover 
where markets are not operating perfectly, state intervention is needed to stimulate and 
discipline entrepreneurial behaviour.  
  
While noting the dominance of ‘liberal market capitalism’, Clift and Woll (2012) highlight 
the inadequate consideration of the role of the state in the comparative literature. In 
developing theory on economic patriotism, they flag up the great expansion in state economic 
intervention since the 2008 financial crisis aimed at promoting economic growth and welfare 
at national, sub-national and sectoral levels. This has been evident in liberal market 
economies such as the US and UK as well as others countries, with renewed interest in 
particular in industrial policy (ibid.). Previous empirical work by both economic sociologists 
and political scientists demonstrates the validity of these observations regarding the role of 
the state in liberal market economies (O’Riain 2004; Weiss 2010).  
 
From an employment relations and labour process perspective, the policy prescriptions for 
states in liberal market economies contained in the models of capitalism literature are highly 
problematic. The analysis of Hall and Soskice (2001) and colleagues leads to the conclusion 
that in liberal market economies the free operation of market forces should be accentuated as 
far as possible. In addition, governments in liberal market economies are seen to be advised 
to concentrate industry support measures on sectors characterised by ‘radical innovation’ 
(e.g. biotechnology) that are best supported by flexible institutional frameworks (Casper 
2007).   
 
However numerous researchers have identified how deregulated, market-based systems 
create undesirable employment outcomes, including high levels of wage inequality, work 
intensification and job insecurity; and often provide limited opportunities for career 
progression and skills development for many workers (e.g. Finegold and Soskice 1988; 
Burchell, Lapido and Wilkinson 2002; Beynon et al. 2002; Green 2006).  
 
Employment researchers are therefore interested in the scope for alternative approaches to 
economic management in liberal market economies to underpin more desirable employment 
outcomes, across a range of sectors. Following the discussion above, the potential of an 
active state industrial policy is currently of particular relevance (Hannon et al. 2011). We 
next consider the definition and forms of industrial policy.  
 
Defining and Identifying State Industrial Policy    
Following Johnson (1984: 8), we define industrial policy as concerned with ‘the initiation 
and co-ordination of governmental initiatives to leverage upward the productivity and 
competitiveness of the whole economy and of particular industries in it.’ The question of 
which policy mechanisms come within the realm of industrial policy is much debated (Coates 
1996). We can nevertheless draw on the work of Block (2008) and others in identifying key 
state activities in this regard.  
 
Block (2008) outlines four key ways in which states endeavour to pursue technology policy 
objectives. States engage in targeted resourcing, which involves identifying particular 
technological problems or areas of potential economic importance, and providing financial 
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resources to support firms and other institutions in working on these. Second, states can 
engage in opening windows, which Block (2008: 172-173) explains involves governments 
supporting more bottom-up, less targeted innovation by providing funding and other support 
to many different projects and institutions.  
 
Third, states engage in technological and business brokering. The former involves connecting 
different actors or groups so that they can take advantage of each other’s knowledge. 
Business brokering includes helping technologists attempting to commercialise a product 
obtain the required funding, make necessary business connections and identify potential 
customers. Finally, facilitation encompasses a wide range of activities such as creating 
appropriate regulatory frameworks for new products or ensuring suitable physical 
infrastructure is in place.  
 
Other key industrial policy activities identified in the literature include the creation of 
financial incentives, for example in the form of taxation rates or R&D tax credits; attraction 
of foreign direct investment; developing capabilities (for example general research 
capabilities or workforce education and training); and public procurement (Porter 1990; 
Huggins and Izushi 2007; Weiss 2010). These various concepts can be used to evaluate state 
industrial policy in specific sectors. We now consider the role of state industrial policy in the 
UK pharmaceutical sector.   
 
Industrial Policy and the UK Pharmaceutical sector 
Pharmaceuticals is a sector in which the role and importance of industrial policy is very 
apparent. In developing new products, pharmaceutical firms need to draw on research 
conducted by universities and research institutes, and they also rely on these actors to supply 
them with an educated workforce (Van Egeraat and Barry 2008). Similarly, they require close 
relationships with health sector organisations in order to test the clinical utility of new 
products as well as find buyers for them. In addition, given the extremely expensive nature of 
new product development in the sector, any financial incentives that governments or other 
actors can provide are much sought after (ibid; Thomas 1994).  
 
Various aspects of the industrial policy context historically promoted the development of the 
UK pharmaceutical sector, including demanding product safety requirements imposed by 
national regulatory agencies; the development and expansion of the National Health Service; 
the favourable rules of the UK’s pricing system for pharmaceutical products; the very strong 
public science base; and the government’s strategic attraction of foreign direct investment of 
an innovative nature (Thomas 1994; Lane and Probert 2003; Slinn 2005). Although not 
without its critics (Froud et al. 1998), pharmaceuticals is frequently highlighted as one of the 
success stories of the British economy, while a strong biotech/biopharma industry has also 
been developed (Lawton-Smith and Bagchi-Sen 2006).  
 
Over the last 10-12 years industrial policy towards the sector has become progressively more 
active. The Labour government established the Pharmaceutical Industry Competitive 
Taskforce in 2000 to examine the competitive position of the industry (PICTF 2001). This led 
to the establishment of the Ministerial Industry Strategy Group, which has since met twice a 
year, bringing together industry and government representatives to discuss key issues 
affecting the sector.  
 
The Office for Life Sciences was set up in January 2009 as a cross departmental body with 
the task of promoting the competitiveness of the UK life sciences sector. Various working 
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groups comprising representatives from government, industry and academia were formed, 
which led to the development of an overarching ‘blueprint’ document in 2009 and subsequent 
progress report in early 2010 (OLS 2009, 2010).  
 
The policies of the Conservative-Liberal government have built closely on those of its 
predecessor. Pharmaceuticals and biopharmaceuticals are seen, within the context of the 
wider life sciences sector, as being industries of great strategic importance, and they benefit 
from very substantial and hands-on support. The government presented its Strategy for UK 
Life Sciences in December 2011 (BIS/OLS 2011). This outlined thirty one specific actions to 
be implemented, with progress and additional initiatives outlined in a report published in 
December 2012 (HM Government 2012a).  
 
The various actions and initiatives include examples of each of the ways in which states may 
act in the industrial policy sphere outlined above. A high profile example of Block’s (2008) 
‘targeted resourcing’ and ‘opening windows’ categories is the Biomedical Catalyst 
Programme. Funded to a total of £180 million over three years and managed by the Medical 
Research Council and the Technology Strategy Board, this involves the provision of grants to 
small and medium enterprises and universities to develop innovative solutions to particular 
biomedical challenges. Support is provided for feasibility, early and late stage projects. By 
the end of 2012, £49 million had been committed to 64 projects, with an additional £25 
million of private sector funds leveraged from this (HM Government 2012a: 9). 
 
An important government objective announced in 2012 is to enable UK institutions and 
businesses to tap into the enormous therapeutic and commercial potential of genomic 
research. The government has outlined measures aimed at combining the UK’s existing 
strengths in genome research with the National Health Service’s status as a world-leading and 
data rich healthcare system, to create a framework from which innovative genome related 
products, technologies and services may be developed (HM Government 2012a). The 
Department of Health is to invest £100 million to fund the sequencing of 100,000 whole 
genomes, support the linking of data and treatment options, and aid the development of 
related skills. Additional funding will be provided by the Medical Research Council and the 
Technology Strategy Board (ibid: 45-47).  
 
In addition to opening windows, this is arguably an example of ‘facilitation’ (Block 2008). In 
this example as well as throughout the life sciences strategy as a whole, there is a strong 
emphasis on harnessing the National Health Service’s role as procurer and user of medicines 
and treatments to the advantage of both industry and patients. The initiatives listed also 
involve the government and its related agencies in ‘brokering’ activities (Block 2008). A 
notable feature is the support for collaborative projects between firms, universities and 
National Health Service institutions.  
 
The creation of financial incentives is also clearly evident. In direct response to lobbying and 
policy critique on the part of the life science sector, the Conservative-Liberal government 
introduced a ‘patent box’ system from April 2013. This applies a lower tax rate (10%) to 
profits from patents developed and commercialised in the UK, with the expectation that this 
will create incentives for firms to develop and commercialise products in the country. This 
measure sits alongside the progressive reduction of corporation tax from 26% to 20% and 
ongoing refinements to the R&D tax credit scheme.   
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The attraction of foreign-direct investment is an important focus, with the government agency 
UK Trade & Investment having developed a specially tailored life sciences marketing and 
promotion campaign. From August 2012 this has been the responsibility of a dedicated unit 
within UK Trade & Investment, the Life Sciences Investment Organisation.  
 
A number of the measures outlined above can be said to ‘develop capabilities.’ Other 
initiatives in this regard relate to skills and training. The Strategy for UK Life Sciences 
outlined the objective of increasing the number of apprenticeships and industry placements 
being taken up in the life sciences sector. Cogent, the state-funded Sector Skills Council for 
process industries, introduced a Higher Level Apprenticeships in Life Sciences in 2012, as 
well as a Technical Apprenticeship Service that supports employers in the recruitment, 
selection and training of apprentices (HM Government 2012a: 53). 
  
Performance and Employment Outcomes 
As outlined above, the industrial policy context historically promoted the development of the 
UK pharmaceutical sector. Alongside increasing demand for pharmaceutical products 
underpinned by rising levels of economic welfare and the expansion of national health 
systems, this supported sustained levels of high growth in the UK sector from the 1950s to 
the 1980s (Froud et al. 1998; Slinn 2005). The number of R&D professionals employed 
expanded significantly during the 1950s, while total employment in the sector increased from 
60,000 in 1963 to 80,000 in 1992 (Froud et al. 1998: 562; Slinn 2005: 182).  
 
Over the last two decades the world pharmaceutical sector has been characterised by 
enormous turbulence. In the 1980s incumbent firms came under increasing pressure due to a 
decline in the rate of successful new drug development; shorter effective patent life due to 
lengthier development and approval processes; downward pressure on margins exerted by 
cost-conscious national governments; and increased competition from manufacturers of 
generic drugs (Froud et al. 1998; Van Egeraat and Barry 2008). These pressures prompted 
very significant rationalization within the UK industry from the early 1990s, involving 
various acquisitions and mergers between firms as well as cost-cutting within individual 
businesses (Froud et al. 1998). 
 
This process of change and rationalization is ongoing. Outsourcing activities such as the 
conduct of molecule screening or later stage clinical research has become commonplace, 
while there is a move among the leading firms to target investments in fundamental research 
to emerging countries such as China and India (Ernst and Young 2010). In addition, the 
progressive development of the medical biotechnology sector has challenged existing firms 
and operating models. This has led to a shift in innovation to small firms and greater 
collaboration between them and the larger incumbents (ibid).  
 
The employment consequences of these processes have been evident in the UK in recent 
years. The US multinational Pfizer closed its flagship R&D facility at Sandwich in Kent in 
2011 with the loss of 1,800 jobs, although this was partially offset by an expansion of the 
company’s Cambridge research centre. AstraZeneca, a leading Anglo-Swedish firm, 
announced the closure of its principal UK R&D site in Cheshire in March 2013 with the loss 
of 550 jobs, having previously undertaken substantial job cuts in 2010 and 2012. 
AstraZeneca’s R&D activity is now to be located in Cambridge, where a new facility 
employing 1,600 scientists will be opened. The extent of the reduction in R&D jobs at these 
and other larger firms is reflected by the fact that the Royal Society of Chemistry estimated 
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there to have been a 20% drop in the number of its members doing pharmaceutical research 
since 2008 (RSC 2011).  
 
Recent trends and those in R&D in particular, are seen by industry officials and company 
managers to be primarily due to competitive trends in the pharmaceutical sector as opposed 
to deficiencies in the UK policy context (House of Commons Science and Technology Select 
Committee 2011; HM Government 2012a). Some critics disagree, arguing that despite the 
various initiatives the UK government does not invest sufficiently in science and technology, 
with MNCs preferring to invest in countries such as the US and China where investment is 
far greater (Mazzucato 2011). In manufacturing the UK has lost jobs to countries such as 
Singapore and Ireland that offered more attractive financial incentives for investment. Jobs 
have similarly been lost in clinical trial related activities due to perceived weaknesses in 
relevant policies and processes (Whitehead 2013). A major perceived weakness is the 
persistently low adoption by the NHS of new medicines, with the Association of the British 
Pharmaceutical Industry highlighting this as a serious impediment to innovation and 
investment (ABPI 2013).   
 
While the latter constitute perceived weaknesses and negative effects of the UK policy 
context, other recent announcements reflect efforts to improve the policy framework for the 
sector. In March 2012, in direct response to the government’s decision to introduce the patent 
box system and reduce corporation tax, the British company GlaxoSmithKline announced a 
£500 million investment in UK manufacturing, which is expected to lead to the creation of 
1,000 jobs. Notably this includes the opening of a new biopharmaceutical manufacturing 
facility. In partnership with the government, other public agencies and the Wellcome Trust, 
GSK has also invested in an open innovation bioscience campus with potential to house 1500 
scientists. 
 
Other positive developments in the last few years include the US multinational Lilly opening 
a new neuroscience R&D facility supporting the work of 130 scientists, and the establishment 
by three other pharma MNCs, Astellas, Eisai and Quintiles, of European headquarters in the 
UK. Lilly’s management expressly highlighted the UK’s world class reputation in 
neuroscience as central to that firm’s new development, with representatives from the other 
firms also mentioning the advantages of UK government policy and the broader 
environmental context. As noted above, Pfizer has expanded its existing R&D centre at 
Cambridge, while AstraZeneca is to open a new facility there. AstraZeneca’s CEO identified 
the UK government’s support for life sciences and the very strong biomedical cluster in 
Cambridge as key reasons behind the latter decision.   
 
Officials from the Bioindustry Association, which represents biomedical firms, note that the 
government’s Biomedical Catalyst, patent box and corporation tax initiatives have 
significantly strengthened investment and business confidence in that sector (BIA 2013). 
They nevertheless continue to call for additional investment support (ibid). 
 
Despite fluctuations, overall pharmaceutical employment remained largely stable between 
1995 and 2010 (ABPI 2011). A recent government report outlines that there are 
approximately 96,000 people working in pharmaceuticals and medical biotechnology in the 
UK (HM Government 2012b). Employment in the former decreased by 10% between 2011 
and 2012, reflecting the ongoing rationalization at the larger firms outlined above. In contrast 
numbers in medical biotechnology increased slightly, by 0.3%.  
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Turnover in UK pharmaceuticals and medical biotechnology in 2012 was approximately £30 
billion and £4 billion respectively (ONS 2012a). The pharmaceutical sector invested £5 
billion in Business R&D in 2011, which represented 28% of total UK investment, and has a 
positive trade balance of almost £7 billion (ONS 2012b; BIS 2012: 47). Provisional data from 
the Annual Survey of Hours and Earnings show that in 2012 the median gross hourly wage in 
pharmaceuticals was £16.20, compared with £12.15 for manufacturing as a whole and £11.26 
for all UK employees. Cogent (2010: 11) estimates that 58% of the pharmaceuticals 
workforce is educated to National Vocational Qualification level 4 or above (i.e. degree level 
or above), compared with under 32% for the labour force as a whole. 
 
Industrial Policy and the UK Food Processing Industry 
The UK food manufacturing industry historically developed largely incrementally and 
autonomously. Small, family owned businesses that supplied local or regional markets were 
commonplace, in particular in traditional food sectors such as bread, meat and dairy (Burns 
1983; Smith, Child and Rowlinson 1990). In contrast, newer products and activities such as 
chocolate manufacture that were marketed and advertised nationally, lent themselves more 
readily to increased scale and the use of mass production technologies (Smith et al. 1990).   
 
While state industrial policy was not central, government action and policies were 
nevertheless important in facilitating the development of the sector, for example by 
regulating the marketing and safety of food products (Burns 1983; Burden 1996; French and 
Phillips 2000). As with pharmaceuticals, the ability of food manufacturers to draw on the 
research capabilities of UK universities, has historically aided innovation in the sector 
(Armstrong 2003). The government’s limited regulation of monopolies and mergers within 
the industry as well as market share in food retailing, was seen to underpin the dramatic 
concentration that took place from the 1960s (Burns 1983; Smith et al. 1990).  
  
One area of the food industry in which government action was historically more prominent is 
dairy processing. From the 1930s until 1994, Milk Marketing Boards established by 
government operated as monopoly purchasers of raw milk across the UK, setting the farm 
gate price of milk for both the liquid and manufacturing sectors using a system of ‘end-use 
pricing’ (Banks 2000). The system also provided dairy processors with fixed and typically 
high margins for the production of specified products.  
 
Central objectives of this regulatory framework were to secure a high milk price for farmers 
and to promote the development of dairy processing. Important public good structures were 
established, notably a collaborative research and development programme and shared-use 
pilot plant facilities (Armstrong 2003). However the Conservative government deregulated 
the dairy industry in 1994, which led to the break up of this system and related institutions 
(ibid.). 
  
Since the 1990s, UK government policy relating to dairy and other sub-sectors of the food 
industry has placed a strong emphasis on promoting competition and efficiency, with 
progressively more attention also devoted to achieving environmentally friendly, sustainable 
production that underpins healthy consumption patterns (DEFRA 2002a and b; Cabinet 
Office 2008; HM Government 2010).  
 
The New Labour governments did not see food manufacturing as a strategic industry from an 
industrial policy perspective. The Conservative-Liberal government is developing a strategy 
for the ‘agri-tech’ sector aimed at harnessing the UK’s strengths in agricultural science and 
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technology to develop products and technologies promoting efficient and sustainable 
production (BIS 2012). The focus here appears predominantly on agriculture, which food 
industry representatives have challenged (All-Party Parliamentary Food and Drink 
Manufacturing Group 2012).  
 
The government and related agencies have nevertheless adopted a range of measures relevant 
to food manufacturing in recent years. The Technology Strategy Board opened a Food 
Processing and Manufacturing Efficiency competition, funded by the Technology Strategy 
Board, the Department for the Environment, Food and Rural Affairs and two research 
councils. This focused on encouraging more efficient processing, packaging and distribution, 
and the recycling of by-products and waste; with successful projects granted up to 50% 
public funding (from £100k to £2.5m). In December 2012, £11 million was awarded for 32 
collaborative research projects involving businesses and academic or research institutions.  
 
The Technology Strategy Board also operates a Nutrition for Life competition, which 
supports new product development aimed at developing healthier, safer and more nutritious 
food. In 2011, £6.5 million was awarded for 27 major collaborative projects focused on the 
development of innovative technologies or processes. In addition, 24 small and medium 
enterprises were supported in carrying out small-scale technical feasibility studies (obtaining 
up to £25,000 each). Food manufacturing firms can also apply for funding under the TSB’s 
High Value Manufacturing competition.  
 
While total public expenditure on agriculture and food research is substantial (for example 
totalling £415 million in 2008/9), the emphasis tends to be on agricultural or more 
fundamental food research as opposed to ‘near market’ research that would be of potential 
application by processing firms. 
 
In January 2012 DEFRA published a Plan of Action on Driving Export Growth in the 
Farming, Food and Drink Sector (DEFRA 2012a). This was drawn up together with UK 
Trade & Investment and representatives from four trade associations. The development of 
specific action points was overseen by the Agri-food and Drink Exports Forum, comprising 
top exporting companies and co-chaired by the Minister of State for Farming and Food and 
the CEO of Nestlé UK. 
 
The Action Plan identified the potential of food and drink exports to drive growth in the agri-
food sector and in that way contribute to the wider development of the UK economy. 
Relevant activities and initiatives announced included the holding of regional events to 
encourage companies to export; making export paperwork simpler and easier for companies 
to access; and financially supporting inexperienced companies to showcase their products at 
international trade shows (ibid). Government ministers have committed to promoting British 
produce abroad.  
 
The Conservative-Liberal government is also taking action intended to better regulate 
processor-retailer relationships. The Groceries Code Adjudicator Bill 2012-13 is currently 
going through parliament and when implemented will establish an adjudicator to monitor and 
enforce the Groceries Supply Code of Practice, which applies to large retailers. The intention 
is to better protect farmers and food processors in their dealings with the latter.  
 
Finally, food manufacturing firms are drawing on the government’s funding of 
apprenticeship training, which amounted to £1.5 billion for 2012-13. The Food and Drink 
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Federation announced a target of doubling the number of apprentices in the sector between 
August 2011 and December 2012. This was more than achieved, with the number of 
apprentices increasing from 1,700 to 4,700 (FDF 2012a). The industry was assisted in this 
process by two publicly funded organisations, the National Apprenticeship Service and the 
National Skills Academy for Food and Drink (ibid.). 
 
Performance and Employment Outcomes 
Historically food and drink manufacturing has been an area of strength for the UK economy. 
While US multinationals assumed powerful positions in the industry, British-owned firms 
remained dominant into the 1980s (Smith et al. 1990). As outlined earlier, the sector 
witnessed very substantial concentration from the 1960s, with industry structures becoming 
rather oligopolistic. Food retailers became more powerful during the 1970s, prompting 
further rationalization within the industry (ibid.).   
 
The position of retailers has become even stronger over recent decades and combined with a 
relative decline in consumer expenditure on food and an increase in imports, this placed 
substantial downward pressure on turnover levels within the UK industry (James and Lloyd 
2008: 212). As a consequence the UK fell behind Germany and France to become the third-
largest food manufacturer in Europe (ibid.).      
 
In the dairy sector, deregulation by the Conservative government in 1994 led to enormous 
turbulence. Combined with a short-term financial orientation characteristic of many larger 
British firms, the difficult competitive conditions prompted a number of indigenous 
companies to curtail investment in new product development and exit the industry. A 
consequence of this was a significantly reduced presence on the part of indigenous firms in 
higher value activities such as the manufacture of yoghurt and desserts, which instead 
became dominated by foreign MNCs (Hannon 2005).  While working conditions at the latter 
are potentially highly desirable, in the lower value, commodity-type markets for milk and 
cheese, low pay, work intensification and a lack of training and development are 
commonplace (Hannon 2005, 2010).  
 
Case study research on other food sectors has similarly identified a notable deterioration of 
working conditions in recent years, with wages in relative decline, benefits being cut back 
and work intensified (James and Lloyd 2008, Edwards et al. 2009; Newsome et al. 2009; 
Hopkins 2012). In addition, food processing employers are making greater use of flexible 
labour practices and many are reliant on migrant workers to fill positions. The flexible and 
light-touch regulatory framework and the emphasis on the free operation of market forces on 
the part of the UK government, are seen to underpin these outcomes (James and Lloyd 2008, 
Edwards et al. 2009; Newsome et al. 2009). While job quality has in general therefore 
deteriorated, there is significant heterogeneity within the industry. Working conditions at 
large branded manufacturers and some foreign-owned MNCs operating in commodity type 
sectors can be comparatively good (FDF 2012b; Hannon 2005, 2010).  
 
The food manufacturing sector has nevertheless performed quite strongly over the last few 
years, with a 9% increase in industry turnover between 2008 and 2011 (ONS 2012a). 
Notably, food and drink continues to be the UK’s largest manufacturing sector by both 
turnover and employment, with turnover of £72 billion in 2011 (ibid.). Exports of agri-food 
products have also grown rapidly since 2005 (Defra 2012; FDF 2012). The UK still however 
has a very large trade deficit in food, feed and drink of £18.6 billion (Defra 2012: 37). The 
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food manufacturing sector invested £350 million in business R&D in 2011, which accounted 
for two percent of total UK expenditure (ONS 2012b). 
 
Industry officials have highlighted and acknowledged the recent support provided to the 
sector by the UK government and state agencies (FDF 2012). At the same time, they identify 
various areas for improvement and express the view that in comparison with other sectors, 
food manufacturing has received relatively little industrial policy assistance (The Engineer, 
May 9, 2011).  
 
The Director General of the Food and Drink Federation has stated that the industry does not 
receive the support needed to undertake the radical innovation required to stay ahead of 
international competition, highlighting a lack of funding for applied research. She has called 
for a strategy to be developed for the sector and for government to work with the industry to 
assess objectives for R&D and innovation and allocate funding to these (All-Party 
Parliamentary Food and Drink Manufacturing Group 2012).  
 
Total employment in UK food manufacturing fell from 510,000 in 1998 to 381,000 in 2010, 
reflecting continual rationalization in the sector. Provisional data from the Annual Survey of 
Hours and Earnings show that in 2012 the median gross hourly wage for the manufacture of 
food products was £9.17. This compares unfavourably with the figures for the wider 
manufacturing sector outlined earlier. James and Lloyd (2008: 217) note how one third of 
process operatives in the sector are paid below the low-pay threshold, with the dominance of 
low-skill jobs reflected by the fact that over half of the sector workforce does not possess the 
equivalent of a school-leaving qualification (ibid.).  
 
Analysis and Conclusion 
The research undertaken identified important differences in employment outcomes between 
the pharmaceutical and food manufacturing sectors. In pharmaceuticals there has and 
continues to be substantial change in the composition of employment, with high profile 
recent job losses at larger firms. However total numbers across the sector as a whole remain 
comparatively stable, with jobs being highly skilled and paid. In contrast, numbers employed 
in food manufacturing have fallen substantially, with a notable deterioration in working 
conditions and job quality in evidence in recent years.  
 
While wider sectoral characteristics and trends are key, the research findings highlight the 
importance of state economic policy in influencing processes and outcomes within both 
sectors. The government has historically played a central role in shaping the development of 
the UK pharmaceutical sector, with a plethora of measures and initiatives involving very 
sizable financial resources in evidence in recent years. Although subject to criticism, these 
measures have helped UK pharmaceutical companies maintain a strong competitive position 
as well as enter new markets and activities. This in turn has supported employment and job 
quality in the sector.  
 
In contrast, food manufacturing in the UK historically developed more autonomously and 
government policy towards that sector has prioritised the free operation of market forces, 
albeit with some recent signs of a more active approach. While relevant indicators reflect 
promising performance over the last few years, UK food manufacturers continue to lag 
behind their foreign counterparts in terms of innovation and presence in higher value market 
segments. The intense competitive environment and flexible regulatory framework has led to 
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extensive rationalisation of employment and causes many of the remaining jobs in the sector 
to be characterised by low wage and skill levels and work intensification.  
 
These findings highlight the problematic nature of dominant paradigms and policy 
prescriptions regarding the role of the state in liberal market economies within the literature 
on comparative capitalism. The evidence from food manufacturing demonstrates the negative 
consequences for employment and working conditions of the predominant reliance on market 
forces to regulate and promote economic activity in liberal market economies, envisaged by 
Hall and Soskice (2001) and colleagues. The findings from food also challenge the 
suggestion that governments in liberal market economies should focus economic support on 
certain sectors to the exclusion of others (Casper 2007).  
 
In contrast, the evidence from pharmaceuticals points to the potential for and positive 
employment effects of an active state industrial policy, even in liberal market economy 
contexts (Hannon et al. 2011). The identification of state industrial policy as a key 
determinant of competitive and employment outcomes is particularly pertinent at the current 
time, as the credit crunch and recession have prompted an increase in state intervention in the 
economic sphere (ibid; Clift and Woll 2012). In this regard, the chapter responds to 
Thompson and Vincent’s (2010) call for more research on the ‘connective tissue’ between the 
labour process and the broader political economy.  
 
Our findings and analysis support the work of authors who have criticised prevailing 
conceptions of the role of the state in liberal market economies (Block 2008; Weiss 2010; 
Clift and Woll 2012). While the UK is commonly identified as a country in which the state 
focuses primarily on ensuring the free operation of market forces, the reality is more 
nuanced. The evidence from pharmaceuticals in particular provided detailed examples of the 
various general ways in which governments can intervene from an industrial policy 
perspective, contrary to dominant conceptions regarding the role of the state in liberal market 
economies (Hall and Soskice 2001; Block 2008; Weiss 2010). 
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